(1995) Malnutrition in stroke patients on the rehabilitation service and at follow-up: Prevalence and predictors
(2021), Lancet 397(10286), PubMed 33894838 Statistics from preclinical literature Cagrilintide (development code AM833 ), a long-acting amylin analogue , 32 amino acids, molecular weight 3.795 kDa Developed at Novo Nordisk (Denmark) as part of the CagriSema combination program (cagrilintide + semaglutide) Target: amylin receptors (AMY1, AMY2, AMY3) + secondarily the calcitonin receptor , extended half-life via a C16 fatty acid linker Standard dose in clinical trials: 0.164.5 mg/week subcutaneously (Phase 1b/2) Phase 2 (Enebo 2021, n=96): 17.1 % reduction in body weight with CagriSema 2.4 mg + 2.4 mg over 20 weeks vs 9.8 % with semaglutide alone REDEFINE 1 Phase 3 (2024, preliminary data): 22.7 % weight reduction with CagriSema 2.4 mg/2.4 mg over 68 weeks Status: Phase 3 completed 20242025 , FDA filing expected 20252026 Approximately 25+ peer-reviewed publications in PubMed (20182024) Reference sources (PubMed) Enebo LB
Caveats and future implications Readers should note that this was a computational study with validation from spray transport observations in inanimate solid replicas
A comparative analysis of the stomach microbiota of gastric cancer patients was performed in a relatively recent study and it was found that there were similarities between the microbiota of gastric cancer patients, dyspepsia patients and those with normal gastric mucosa ( Helicobacter abundance, along with an increase in the relative abundance of genera such as Lactobacillus , Citrobacter , Achromobacter , Clostridium , and Rhodococcus
Some metallodrugs have been synthesized and tested for their combined, SOD and catalase scavenging activities
